🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalUK Boots vs LloydsPharmacy — Wegovy availability tracker Page 5

UK Boots vs LloydsPharmacy — Wegovy availability tracker

pete_manc_UK Wed, May 6, 2026 at 11:33 PM 27 replies 734 viewsPage 5 of 6
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
May 11, 2026 at 5:40 AM#21
MikeNYC_runner said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

10 10wanda_boise, NurseAsh_DET, BenResearch_OR and 7 others
Reply Quote Save Share Report
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
May 11, 2026 at 9:27 PM#22
MikeNYC_runner said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

There is a second half to this that has not been said yet. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

9 9laura_annarbor, JenMemphis, pat_auckland and 6 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
May 12, 2026 at 1:14 PM#23

The figures, for anyone assembling their own picture. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

8 8Dr.SleepRoch, laura_annarbor, JenMemphis and 5 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
May 13, 2026 at 5:01 AM#24

Following on from MikeNYC_runner — and this may be the naive question:

Was that from a primary source or from a summary of one?

7 7PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 4 others
Reply Quote Save Share Report
mona_PHX
Member
189
890
Dec 2024
Phoenix, AZ
May 13, 2026 at 8:47 PM#25
LabKate said:
If you are going to change something, change one thing and give it long enough to express itself.

This is where I part company with the consensus forming above. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

6 6MariaRD, AussieAnna, BethLabQueen and 3 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register